We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

66 hedge funds and large institutions have $130M invested in Palvella Therapeutics in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

35% more funds holding

Funds holding: 49 → 66 (+17)

14% more capital invested

Capital invested by funds: $114M → $130M (+$16.3M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 0.65% → 0.64% (-0.02%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $95K

Holders
66
Holders Change
+17
Holders Change %
+34.69%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
17
Reduced
10
Closed
5
Calls
–
Puts
$95K
Net Calls
-$95K
Net Calls Change
-$95K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$1.5M
2
BIM
Bogle Investment Management
Massachusetts
+$1.15M
3
Millennium Management
Millennium Management
New York
+$1.1M
4
Cerity Partners
Cerity Partners
New York
+$856K
5
JP Morgan Chase
JP Morgan Chase
New York
+$545K

Top Sellers

1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$3.66M
2
BI
BVF Inc
California
-$2.7M
3
OFM
Omega Fund Management
Massachusetts
-$871K
4
IBT
International Biotechnology Trust
United Kingdom
-$712K
5
SFM
Sphera Funds Management
Israel
-$534K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$75K – – –
Balyasny Asset Management
52
Balyasny Asset Management
Illinois
$69K +$64.1K +150 New
Parallax Volatility Advisers
53
Parallax Volatility Advisers
California
$67K – – –
State Board of Administration of Florida Retirement System
54
State Board of Administration of Florida Retirement System
Florida
$59K +$55.1K +129 New
US Bancorp
55
US Bancorp
Minnesota
$59K +$55.1K +129 New
SO
56
STRS Ohio
Ohio
$57K – – –
Legal & General Group
57
Legal & General Group
United Kingdom
$29K – – –
TRCT
58
Tower Research Capital (TRC)
New York
$24K +$22.2K +52 New
UBS Group
59
UBS Group
Switzerland
$23K +$20.9K +49 New
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$19.3K -$1.28K -3 -7%
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$18K +$16.7K +39 New
AIP
62
Ameritas Investment Partners
Nebraska
$16K – – –
CHP
63
Cable Hill Partners
Oregon
$12K +$10.7K +25 New
CG
64
Cutler Group
California
$4K +$3.84K +9 New
SEI Investments
65
SEI Investments
Pennsylvania
$3K +$2.56K +6 New
Citigroup
66
Citigroup
New York
$1K – – –
IBT
67
International Biotechnology Trust
United Kingdom
– -$712K -1,763 Closed
TC
68
TFS Capital
Pennsylvania
– -$277K -685 Closed
AIM
69
Acrospire Investment Management
Illinois
– -$6K -15 Closed
Federated Hermes
70
Federated Hermes
Pennsylvania
– -$3K -7 Closed
GWM
71
Geneos Wealth Management
Colorado
– -$1K -4 Closed
1 2
3

PVLA Hedge Fund Activity: Q3 2017 in Review

66 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2017, worth a combined $130M — up 14% from $114M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PVLA positions and 5 closed out — a net gain of 17 holders — while 17 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.5M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $3.66M.

  • 66 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2017, up from 49 in Q2 2017.
  • Funds reported $130M of Palvella Therapeutics stock for Q3 2017, up 14% quarter-over-quarter.
  • 22 funds opened new Palvella Therapeutics positions in Q3 2017 and 5 closed out, a net change of +17 holders.
  • The largest Palvella Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $1.5M added.
  • The largest Palvella Therapeutics seller in Q3 2017 was Lombard Odier Asset Management (USA), an estimated $3.66M sold.

Based on aggregated 13F filings for Q3 2017.